Glucovance

Glucovance is a prescription oral medication that combines metformin hydrochloride and glibenclamide in a tablet. The combination belongs to the biguanide and sulfonylurea classes and is used to improve blood glucose control in adults with type 2 diabetes mellitus. It works by decreasing hepatic glucose production, enhancing insulin sensitivity, and stimulating insulin release from pancreatic β‑cells. Glucovance is available in the European Union and requires a prescription.

Glucovance is indicated for the management of hyperglycemia in adults with type 2 diabetes mellitus, typically when diet, exercise, and monotherapy with either metformin or a sulfonylurea do not achieve target glucose levels.

- As adjunct to diet and exercise, it helps lower fasting plasma glucose. - It can be used to reduce post‑prandial glucose excursions. - The combination may simplify treatment regimens compared with separate tablets. - It is prescribed when a patient requires both insulin sensitization and increased insulin secretion. - Dose adjustments may be considered in patients with renal or hepatic impairment under medical supervision.

The safety profile of Glucovance reflects the known effects of its two components, metformin and glibenclamide.

Common: - Gastrointestinal upset such as nausea, abdominal discomfort, or diarrhea. - Mild hypoglycemia, especially when meals are missed or delayed. - Metallic taste in the mouth. - Weight gain or fluid retention.

Serious: - Severe hypoglycemia with symptoms like confusion, seizures, or loss of consciousness. - Lactic acidosis, a rare but life‑threatening condition associated with metformin. - Allergic reactions including skin rash, itching, or swelling of the face and throat.

Before initiating Glucovance, clinicians should evaluate several clinical factors to minimize risks and ensure appropriate use.

- Assess renal function; metformin is contraindicated in severe renal impairment. - Review hepatic status, as liver disease can increase the risk of lactic acidosis. - Monitor for signs of heart failure; fluid retention may worsen the condition. - Evaluate for a history of hypersensitivity to sulfonylureas or metformin. - Use caution in elderly patients due to increased susceptibility to hypoglycemia. - Advise patients to avoid excessive alcohol consumption, which can potentiate lactic acidosis.

Glucovance may interact with other medicines, affecting blood glucose levels or increasing the risk of adverse events.

Avoid: - Concurrent use of other sulfonylureas or insulin, which can cause profound hypoglycemia. - Iodinated contrast agents in patients with reduced renal function, due to risk of metformin‑associated lactic acidosis. - Strong CYP2C9 inhibitors (e.g., fluconazole) that can raise glibenclamide concentrations.

Use with caution: - Beta‑blockers, which may mask hypoglycemia symptoms. - Diuretics, especially thiazides, that can elevate blood glucose. - Corticosteroids, which may increase insulin resistance. - ACE inhibitors or ARBs, requiring monitoring of renal function when combined with metformin.